US4427650A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Enriched plasma derivative for advancement of wound closure and healing
Assignee: SERAPHARM & Co KG AN FRG CORP GmbH
•
Filing: 1982-06-07
•
Granted: 1984-01-24
•
Expires: 2002-06-07
Abstract
Abstract A preparation for accelerated hemostasis and optimized biochemical control of wound closure ("tissue adhesive") consists only of solid, powdery, biologically active constituents and contains 60 to 96% by weight of fibrinogen, which is largely liberated from cryo-insoluble globulin, 0.05 to 5% by weight of a fibrinolysis inhibitor, and 0.1 to 15% by weight of thrombin and/or prothrombin. For use, this enriched plasma derivative may be applied in the form of a dry, powdery mixture immediately and directly onto the wound or in the area of operation, respectively. Further application methods provide atomizing, spraying, or foaming of the powdery mixture by means of a propellant.
Inventors
- 👤 Michael Stroetmann
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 01:45
CPC Classifications
A; A61; A61L; A61L27/00; A61L27/14; A61L27/22; A61L27/225; A61K; A61K35/00; A61K35/12; A61K35/14; A61K35/19; A61K38/00; A61K38/005; A61K38/16; A61K38/17; A61K38/36; A61K38/363; A61K38/43; A61K38/46; A61K38/48; A61K38/482; A61K38/4833; A61L24/00; A61L24/04; A61L24/10; A61L24/102; A61L24/106; A61L24/108; A61L26/00; A61L26/0009; A61L26/0028; A61L26/0042; A61L26/0057; A61L26/0061; A61L26/0066; A61F; A61F2310/00; A61F2310/00005; A61F2310/00365; A61F2310/00377; A61L2300/00; A61L2300/20; A61L2300/252; A61L2300/40; A61L2300/404; A61L2300/406; A61L2300/418; A61L2300/432
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
81 words
An enriched plasma derivative for supporting wound closure and healing, containing 60 to 96% by weight of fibrinogen and 0.5 to 5% by weight of a fibrinolysis inhibitor, wherein (a) the fibrinogen is largely free from cryo-insoluble globulin; (b) the plasma derivative additionally contains 0.1 to 15% by weight of thrombin and/or prothrombin; (c) all components are present in biologically active, solid powdery form at temperatures of up to 56° C.; and (d) these solid components are mixed with each other.
Claim 2
Dependent Claim
81 words
An enriched plasma derivative for supporting wound closure and healing, containing 60 to 96% by weight of fibrinogen and 0.5 to 5% by weight of a fibrinolysis inhibitor, wherein (a) the fibrinogen is largely free from cryo-insoluble globulin; (b) the plasma derivative additionally contains 0.1 to 15% by weight of thrombin and/or prothrombin; (c) all components are present in biologically active, solid powdery form at temperatures of up to 56° C.; and (d) these solid components are mixed with each other.
Claim 3
Dependent Claim
37 words
A plasma derivative as claimed in claim 1, wherein the fribrinogen is a product obtained from human plasma by precipitation with a mixed solvent containing glycine, β-alanine and ethanol and subsequent dialysis and lyophilization of the precipitate.
Claim 4
Dependent Claim
22 words
A plasma derivative as claimed in claim 1 or 2, wherein the fibrinogen contains less than 2% by weight of cryo-insoluble globulin.
Claim 5
Dependent Claim
17 words
A plasma derivative as claimed in claim 1 or 2, wherein the fibrinolysis inhibitor is an antiplasmin.
Claim 6
Dependent Claim
22 words
A plasma derivative as claimed in claim 1 or 2, wherein prothrombin is present and convertible into thrombin to at least 95%.
Claim 7
Dependent Claim
27 words
A plasma derivative as claimed in claim 1 or 2, wherein thrombin is present and has a biological activity of at least 1,000 international units per mg.
Claim 8
Dependent Claim
34 words
A plasma derivative as claimed in claim 1 or 2, wherein 0.1 to 2 parts by weight of prothrombin are provided per 1 part by weight of thrombin, both thrombin and prothrombin being present.
Claim 9
Dependent Claim
49 words
A plasma derivative as claimed in claim 1 or 2, wherein the plasma derivative contains 80 to 94% by weight of fibrinogen, 1 to 10% by weight of thrombin and/or prothrombin, 0.01 to 3% by weight of the fibrinolysis inhibitor, and less than 0.4% by weight of cryo-insoluble globulin.
Claim 10
Dependent Claim
36 words
A plasma derivative as claimed in claim 1, 2, or 8, wherein the plasma derivative substantially contains a phospholipid, a prostaglandin, a desiccating and stabilizing agent, an antibiotic and/or coagulation factor, all in solid, powdery form.
Claim 11
Dependent Claim
31 words
Method of using the enriched plasma derivative of claim 1, 2, or 8, wherein the dry, powdery mixture is applied directly onto a wound or in the area of an operation.
Claim 12
Dependent Claim
15 words
Method of claim 10, wherein the powdery mixture is provided on a biological carrier material.
Claim 13
Dependent Claim
18 words
Method of claim 11, wherein the biological carrier material is collagen or a natural or synthetic dressing material.
Claim 14
Dependent Claim
21 words
Method of claim 10, wherein the dry, powdery mixture is atomized, sprayed, or foamed in place by means of a propellant.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-01-23 | 1987-07-25 | 1988-01-24 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-01-23 | 1991-07-25 | 1992-01-24 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-01-23 | 1995-07-25 | 1996-01-24 | $7700.00 | Window Closed / Lapsed |